Loading
A phase 3 trial of Camizestrant and Palbociclib in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease is a phase 3 interventional study registered as NCT04711252 by AstraZeneca, with 1370 participants enrolled, started 2021-01-28 and due to reach its primary completion in 2026-08-24. Interventions recorded: AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib and Luteinizing hormone-releasing hormone (LHRH) agonist.
Shares Camizestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Anastrozole, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Camizestrant, Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.